Extent of liver inflammation in predicting response to interferon α & Ribavirin in chronic hepatitis C patients: a cohort study

详细信息    查看全文

• 作者：Shirin Mirza (1) (2)
  Amna Rehana Siddiqui (1) (3)
  Saeed Hamid (4)
  Muhammad Umar (5)
  Shaheena Bashir (6)
  
• 刊名：BMC Gastroenterology
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：12
• 期：1
• 全文大小：417KB
• 参考文献：1. Hepatitis C In / Fact sheet no. 164. Geneva: World Health Organization; 2011.
  2. Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HUR: Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. / East Mediterr Health J 2010,16(Suppl):15-3.
  3. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH: Pathogenesis, natural history, treatment, and prevention of hepatitis C. / Ann Intern Med 2000,132(4):296-05.
  4. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RNM, Phillips J, Portmann BG, Poulsen H, Scheuer PJ, Schmid M, Thaler H: Histological grading and staging of chronic hepatitis. / J Hepatol 1995,22(6):696-99. CrossRef
  5. Hamid S, Umar M, Alam A, Siddiqui A, Quresh H, Butt J: PSG consensus statement on management of hepatitis C virus infection-2003. / J Pak Med Assoc 2004,54(3):146-49.
  6. Umar M, Khaar HB, Khan AA, Mohsin A, Din W, Shah HA, Mohammad N, Ahmed M, Naqvi AA, Khurram M, Qureshi S, Ahmad I, Ahmad M, Ejaz K, Ambreen S, Adam T, Mahmood Z, Naeem A, Arif A, Bhutta S: Diagnosis, management and prevention of hepatitis C in Pakistan 2009. / Pak J Gastroenterol 2009,23(2):7-7.
  7. Davis GL, Lau JY: Factors predictive of a beneficial response to therapy of hepatitis C. / Hepatology 1997,26(Suppl3):122-27. CrossRef
  8. Keeffe EB: / Role of Liver Biopsy in Chronic Hepatitis C. San Francisco: HCV Advocate; 2003 [http://www.hcvadvocate.org/hcsp/articles/Keeffe-1.html].
  9. Lee SS: Indicators and predictors of response to anti-viral therapy in chronic hepatitis C. / Aliment Pharmacol Ther 2003,17(5):611-21. CrossRef
  10. Strader DB, Wright T, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C. / Hepatology 2004,39(4):1147-171. CrossRef
  11. European Association for the Study of the Liver: EASL Clinical Practice Guidelines: management of hepatitis C virus infection / J Hepatol 2011,55(2):245-64.
  12. Daboul I, Ghai V, Filipiak C: Does the grade of inflammation on liver biopsy predict the response to combination treatment with pegylated interferon and Ribavirin in hepatitis C patients? [Abstract]. / Am J Gastroenterol 2006, 101:s148-s196. CrossRef
  13. Derbala MF, Kaabi S, El Dweik NZ, Pasic F, Butt MT, Yakoob R, Al-Marri A, Amer AM, Morad N, Bener A: Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage. / World J Gastroenterol 2006,12(35):5692-698.
  14. Prati D, Taioli E, Zanella A, Torre ED, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S: Updated definitions of healthy ranges for serum alanine aminotransferase levels. / Ann Intern Med 2002,137(1):1-0.
  15. Dean AG, Dean JA, Coulombier D, Brendel KA, Smith DC, Burton AH, Dicker RC, Sullivan K, Fagan RF, Arner TG: / Epi Info, Version 6: a word processing, database, and statistics program for public health on IBM-compatible microcomputers. Atlanta, USA: Center for disease control and prevention; 1995.
  16. Lwanga SK, Lemeshow S: / Sample size determination in health studies: a practical manual. Geneva: World Health Organization; 1991.
  17. SPSS In / Version 14.0.0. Chicago: SPSS Inc.; 2005.
  18. Lachin JM: Stratified-adjusted analysis for independent groups. In / Biostatistical methods: the assessment of relative risks. 2nd edition. New Jersey: Wiley Online Library; 2008:119-00.
  19. Schafer JL: / Analysis of incomplete multivariate data. London: Chapman & Hall; 1997. CrossRef
  20. Greiner M, Pfeiffer D, Smith RD: Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. / Prev Vet Med 2000,45(1-):23-1. CrossRef
  21. Koziel MJ, Dudley D, Afdhal N, Grakoui A, Rice CM, Choo QL, Houghton M, Walker BD: HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus: identification of multiple epitopes and characterization of patterns of cytokine release. / J Clin Invest 1995, 96:2311-321. CrossRef
  22. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW: Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. / Hepatology 1996,24(4):759-65. CrossRef
  23. Hu KQ, Vierling JM, Redeker AG: Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. / J Viral Hepat 2001,8(1):1-8. CrossRef
  24. Lu LG, Zeng MD, Mao YM, Li JQ, Qiu DK, Fang JY, Cao AP, Wan MB, Li CZ, Ye J: Relationship between clinical and pathologic findings in patients with chronic liver diseases. / World J Gastroenterol 2003,9(12):2796-800.
  25. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J: Is an “?la carte-combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? / Hepatology 2000,31(1):211-18. CrossRef
  26. Zuberi BF, Zuberi FF, Memon SA, Qureshi MH, Ali SZ, Afsar S: Sustained virological response based on rapid virological response in genotype-3 chronic hepatitis C treated with standard interferon in the Pakistani population. / World J Gastroenterol 2008,14(14):2218-221. CrossRef
  27. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok ASF: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. / Hepatology 2003,38(2):518-26. CrossRef
  28. Davis GL, Lindsay K, Albrecht J, Bodenheimer HC, Balart LA, Perrillo RP, Dienstag JL, Tamburro C, Schiff ER, Carey W: Clinical predictors of response to recombinant interferon- treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). / J Viral Hepat 1994,1(1):55-3. CrossRef
  29. Dor-Mohammadi T, Daryani NE, Bashashati M, Hashtrudi AA, Haghpanah B, Sayyah AR, Shakiba M: Relationship between serum alanine aminotransferase levels and liver histology in chronic hepatitis C-infected patients. / Indian J Gastroenterol 2005,24(2):49-1.
  30. Westin J, Lagging LM, Wejst?l R, Norkrans G, Dhillon AP: Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. / Liver 1999,19(3):183-87. CrossRef
  31. Alavian SM, Kabir A, Hajarizadeh B, Nayebpour M, Beigi BH, Doroudi T, Baralle FE: Combination therapy of interferon-alpha (PDferon B?) and ribavirin for chronic hepatitis C. / Hepat Mon 2004, 4:13-6.
  32. Lee YS, Yoon SK, Chung ES, Bae SH, Choi JY, Han JY, Chung KW, Sun HS, Kim BS, Kim BK: The relationship of histologic activity to serum ALT, HCV genotype and HCV RNA titers in chronic hepatitis C. / J Korean Med Sci 2001,16(5):585-91.
  33. Mumtaz K, Hamid SS, Moatter T, Abid S, Shah HA, Jafri W: Distribution of hepatitis C virus genotypes and its response to treatment in Pakistani patients. / Saudi Med J 2008,29(11):1671-673.
  34. Idrees M, Riazuddin S: A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. / BMC Gastroenterol 2009,9(1):5. CrossRef
  35. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/12/71/prepub
  
• 作者单位：Shirin Mirza (1) (2)
  Amna Rehana Siddiqui (1) (3)
  Saeed Hamid (4)
  Muhammad Umar (5)
  Shaheena Bashir (6)
  
  1. Department of Community Health Sciences, Aga Khan University, Karachi, Pakistan
  2. Public Health Solutions Pakistan, Islamabad, Pakistan
  3. Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia
  4. Department of Medicine, Aga Khan University, Karachi, Pakistan
  5. Department of Medicine, Holy Family Hospital, Rawalpindi, Pakistan
  6. Department of Mathematics and Statistics, McMaster University, Hamilton, Canada
  

文摘

Background Liver inflammation due to HCV infection leads to fibrosis, which is an independent predictor of treatment response to interferon therapy in Chronic Hepatitis C (CHC) patients. This relationship has not been studied for liver inflammation on pretreatment liver biopsy and End of Treatment Response (ETR). ALT is a less invasive test than liver biopsy for measuring liver inflammation. Aim of this study was to compare ETR to Interferon α (recombinant Interferon) & Ribavirin in CHC patients having higher and lower grades of liver inflammation and to determine the diagnostic accuracy of pretreatment ALT for grades of liver inflammation. Methods A retrospective cohort of 876 na?ve CHC patients, who completed Interferon α & Ribavirin for 24?weeks, was studied for ETR. Pretreatment grade of inflammation on liver biopsy was taken as the exposure variable. It was classified as high if there was moderate or severe and low if there was minimal or mild. Multivariable logistic regression modeling was performed. Diagnostic accuracy of pretreatment ALT for liver inflammation grades was determined by computing Area Under the Receiver Operator Curve (AUROC). Results Of all patients, 672 having diagnostic liver biopsy and ETR available were analyzed. Among them, 103 had high and 569 had low grades of liver inflammation. Mean age was 36.9 (SD 9.1) years, with patients with high grades being older than those with low grades inflammation (p--.03). High grades of liver inflammation was associated with ETR (RR 1.17, 95% CI 1.12-.18) adjusting for age, Total Leukocyte count (TLC) and pretreatment levels of ALT, irrespective of liver fibrosis. This relation remained significant for ‘bridging fibrosis and cirrhosis-and not for ‘no-or ‘portal fibrosis- AUROC of pretreatment ALT for males and females was moderately accurate for severe inflammation compared to minimal inflammation and less accurate for high grades compared to low grades. Conclusions ETR in patients with higher grades of liver inflammation was 17% higher than those with lower grades irrespective of fibrosis and 9% higher for bridging fibrosis and cirrhosis. Pretreatment ALT was moderately accurate for severe inflammation only on liver biopsy in both males and females.